Race to Secure COVID-19 Vaccines - What Vaccine Attributes Should Matter Most in Low-to-Middle-Income Countries?
Author(s)
Discussion Leaders: Diego F Guarin, MD, MPH, MA, Merck, Kenilworth , NJ, USA Manuel Antonio Espinoza, MD MSc PhD, Pontificia Universidad Catolica de Chile, Santiago, Chile; Valeria Boers Trilles, MPhil, CBPartners, New York, NY, USA; Miguel Martin De Bustamante, BA, CBPartners, San Francisco, CA, USA
Presentation Documents
PURPOSE:
This workshop will utilize Multi-Criteria Decision Analysis (MCDA) to compare the holistic value of different COVID-19 vaccines from the perspective of Emerging Markets, looking beyond clinical efficacy and safety to consider other factors such as societal value, affordability, storage / distribution requirements to evaluate which vaccine candidates bring most value to developing countries.DESCRIPTION:
As of DEC 2020, four COVID-19 vaccines have received authorization for emergency use in some countries and several other vaccine candidates have reached late-stage trials, which may be an effective tool to manage the coronavirus pandemic by reducing the spread of COVID-19. However, budgetary constraints and challenges in storage and distribution cloud the outlook for many low-to-middle income economies, raising concerns around equitable access. In this workshop, MCDA will be used to compare the holistic value of late-stage vaccine candidates from the perspective of low-to-middle income economies. Results from this analysis can inform prioritization of vaccine candidates by agencies (governments, COVAXX) looking to procure COVID-19 vaccines for developing countries. An overview of the EVIDEM MCDA framework will be provided at the start of the session and the audience will use a real-time polling application to vote on the weight that should be given to different domains and criteria of the EVIDEM MCDA framework to make it applicable for COVID-19 vaccines in the context of developing countries. Then, speakers will conduct a comprehensive comparison of COVID-19 vaccines across different criteria (efficacy, safety, # shots, storage / distribution requirements). The audience will then use a real-time polling application to vote on the value that the different vaccine candidates offer as interventions for COVID-19 immunization. Speakers will close the session by presenting the results from the comparative MCDA for COVID-19 vaccines, contextualizing the implications for decision-makers in low-to-middle income countries, and opening up the floor for questions from the audience.Conference/Value in Health Info
2021-05, ISPOR 2021, Montreal, Canada
Code
W8
Topic
Health Technology Assessment